Ramachandran, Sarath http://orcid.org/0000-0002-0922-9448
Makukhin, Nikolai
Haubrich, Kevin http://orcid.org/0000-0001-5025-3821
Nagala, Manjula
Forrester, Beth
Lynch, Dylan M.
Casement, Ryan
Testa, Andrea
Bruno, Elvira
Gitto, Rosaria
Ciulli, Alessio http://orcid.org/0000-0002-8654-1670
Article History
Received: 18 February 2023
Accepted: 14 September 2023
First Online: 10 October 2023
Competing interests
: The Ciulli laboratory receives or has received sponsored research support from Almirall, Amgen, Amphista Therapeutics, Boehringer Ingelheim, Eisai, Merck KGaA, Nurix Therapeutics, Ono Pharmaceutical and Tocris-Biotechne. A.C. is a scientific founder, shareholder, and advisor of Amphista Therapeutics, a company that is developing targeted protein degradation therapeutic platforms. A.T. and N.M. are currently employees of Amphista Therapeutics. The remaining authors declare no competing interests.